INE963

Small molecule

Phase 1Mechanism not established
Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (3)
Malaria
NCT07811882 · Novartis Pharmaceuticals
2025-10-10 – 2026-07-01 · Uncomplicated Plasmodium Falciparum Malaria
What this study did
NCT05750628 · Novartis Pharmaceuticals
2024-01-23 – 2026-06-23 · Uncomplicated Plasmodium Falciparum Malaria
What this study did
NCT07235020 · Novartis Pharmaceuticals
2024-01-23 – 2025-02-21 · Uncomplicated Plasmodium Falciparum Malaria
What this study did
Phase 1 (1)
Other / comorbidity
NCT04896632 · Novartis Pharmaceuticals
2021-05-13 – 2022-11-24 · Healthy Volunteers
What this study did

Competitive landscape

This drug's own stage for Malaria: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
INE963: this drugStage not on recordSmall molecule—not yet gradedNo reviewed efficacy summary in this indication
Ganaplacide / LumefantrinePhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
CipargaminPhase 2Small moleculePfATP4not yet gradedNo reviewed efficacy summary in this indication
GSK3772701Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
GSK4024484Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
GSK4425689
—(overall)
UndisclosedCircumsporozoite protein (CSP)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.